Generic Fenoglide for High Cholesterol Launched by Mylan


Mylan is releasing a generic version of Santarus' fenofibrate (Fenoglide) tablets.

Mylan is releasing a generic version of Santarus’ fenofibrate (Fenoglide) tablets.

The FDA approved the manufacturer’s abbreviated new drug application for the 40-mg and 120-mg tablets on July 6, 2016.

The product may be used as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B and to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

In the year ending April 30, 2016, fenofibrate tablets had US sales of around $28.6 million, IMS Health reported.

Mylan hopes to receive FDA approval for nearly 250 additional abbreviated new drug applications still pending.

Related Videos
Image credit:  Gorodenkoff |
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin -
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny -
Various healthy foods -- Image credit: New Africa |
LGBTQIA+ pride -- Image credit: lazyllama |
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki |
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba |
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT |
© 2024 MJH Life Sciences

All rights reserved.